Profile data is unavailable for this security.
About the company
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
- Revenue in USD (TTM)0.00
- Net income in USD-129.44m
- Incorporated2020
- Employees186.00
- LocationCompass Pathways PLC3Rd Floor, 1 Ashley RoadALTRINCHAM WA14 2DTUnited KingdomGBR
- Phone+44 1646 905 3974
- Websitehttps://compasspathways.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nkarta Inc | 0.00 | -116.20m | 493.27m | 150.00 | -- | 1.04 | -- | -- | -2.35 | -2.35 | 0.00 | 6.72 | 0.00 | -- | -- | 0.00 | -22.45 | -32.39 | -23.55 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Celcuity Inc | 0.00 | -73.45m | 494.93m | 55.00 | -- | 3.24 | -- | -- | -2.79 | -2.79 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -41.61 | -37.32 | -44.44 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2193 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 502.49m | 19.00 | -- | 5.10 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
| Astria Therapeutics Inc | 0.00 | -81.63m | 504.10m | 59.00 | -- | 1.85 | -- | -- | -2.32 | -2.32 | 0.00 | 6.70 | 0.00 | -- | -- | 0.00 | -27.34 | -64.48 | -28.18 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| Applied Therapeutics Inc | -477.00k | -193.56m | 504.49m | 26.00 | -- | 7.50 | -- | -- | -1.91 | -1.91 | -0.005 | 0.589 | -0.0053 | -- | -- | -19,080.00 | -213.60 | -140.37 | -604.11 | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Allogene Therapeutics Inc | 87.00k | -292.30m | 508.46m | 232.00 | -- | 0.9015 | -- | 5,844.33 | -1.78 | -1.78 | 0.0005 | 2.71 | 0.0001 | -- | -- | 375.00 | -43.85 | -28.46 | -47.04 | -30.21 | -- | -- | -335,973.60 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -108.30m | 509.21m | 118.00 | -- | 4.71 | -- | -- | -3.14 | -3.14 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -68.23 | -33.56 | -75.55 | -36.55 | -- | -- | -- | -941.88 | -- | -- | 0.00 | -- | -- | -- | -12.83 | -- | -3.47 | -- |
| Eyepoint Pharmaceuticals Inc | 50.02m | -78.92m | 509.91m | 121.00 | -- | 1.95 | -- | 10.19 | -1.83 | -1.83 | 1.17 | 5.01 | 0.2068 | 1.14 | 7.44 | 413,380.20 | -32.62 | -40.44 | -40.06 | -47.79 | 90.50 | 83.45 | -157.77 | -186.23 | 5.01 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -129.44m | 510.81m | 186.00 | -- | 1.97 | -- | -- | -2.37 | -2.37 | 0.00 | 3.79 | 0.00 | -- | -- | 0.00 | -53.68 | -40.85 | -57.32 | -44.48 | -- | -- | -- | -- | -- | -43.34 | 0.1009 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Altimmune Inc | 410.00k | -92.77m | 517.59m | 59.00 | -- | 2.99 | -- | 1,262.41 | -1.59 | -1.59 | 0.007 | 2.44 | 0.0022 | -- | 1.47 | 6,949.15 | -49.42 | -39.62 | -53.14 | -42.58 | -- | -- | -22,626.10 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| OmniAB Inc | 21.05m | -63.48m | 522.21m | 106.00 | -- | 1.73 | -- | 24.81 | -0.634 | -0.634 | 0.2103 | 2.57 | 0.055 | -- | 7.18 | 198,547.20 | -16.58 | -- | -17.48 | -- | -- | -- | -301.63 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Absci Corp | 5.35m | -109.19m | 522.45m | 155.00 | -- | 2.17 | -- | 97.71 | -1.17 | -1.17 | 0.0569 | 2.12 | 0.0187 | -- | 7.82 | 34,496.77 | -38.26 | -- | -42.14 | -- | -- | -- | -2,042.01 | -- | -- | -107.74 | 0.0298 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Exscientia PLC (ADR) | 25.07m | -165.34m | 523.77m | 483.00 | -- | 1.80 | -- | 20.89 | -1.31 | -1.31 | 0.1984 | 3.35 | 0.0364 | -- | 34.98 | 51,902.11 | -24.02 | -- | -27.31 | -- | -34.40 | -- | -659.56 | -- | -- | -- | 0.0556 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| Avid Bioservices Inc | 136.74m | -18.26m | 525.61m | 365.00 | -- | 2.92 | -- | 3.84 | -0.2888 | -0.2888 | 2.17 | 2.84 | 0.302 | 3.18 | 4.89 | 374,616.40 | -4.03 | 10.70 | -6.13 | 15.18 | 7.47 | 22.72 | -13.35 | 25.86 | 0.3097 | -4.47 | 0.4548 | 0.00 | 24.81 | 22.72 | -99.80 | -- | 82.98 | -- |
Data as of Jun 07 2024. Currency figures normalised to Compass Pathways PLC's reporting currency: US Dollar USD
25.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 02 Apr 2024 | 3.89m | 5.69% |
| Citadel Advisors LLCas of 31 Mar 2024 | 3.81m | 5.58% |
| Paradigm BioCapital Advisors LPas of 31 Mar 2024 | 2.39m | 3.50% |
| ARK Investment Management LLCas of 31 Mar 2024 | 2.16m | 3.16% |
| PFM Health Sciences LPas of 31 Mar 2024 | 1.09m | 1.59% |
| Affinity Asset Advisors LLCas of 31 Mar 2024 | 1.03m | 1.50% |
| Aisling Capital Management LPas of 31 Mar 2024 | 964.50k | 1.41% |
| RA Capital Management LPas of 31 Mar 2024 | 791.36k | 1.16% |
| Rosalind Advisors, Inc.as of 31 Mar 2024 | 734.00k | 1.07% |
| Soleus Capital Management LP (Investment Management)as of 31 Mar 2024 | 565.55k | 0.83% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
